Cancers of high unmet need are missing out on new drugs seen for other tumours.
•
Very few targeted drugs are coming through to the clinic for paediatric cancers.
•
It is taking too long to deliver new drugs to patients.
•
We need radical innovation to overcome cancer evolution and drug resistance.